Payment overview · 2025
General Payments
$145.19
9 reported records · 2 companies
Healthcare provider profile · identity verified
Daniel Martin, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · N DARTMOUTH, MA · NPI 1720058803
Verified facts
What the public records show
CMS Open Payments records show Daniel Martin, MD received $145.19 in general payments during 2025 across 9 reported records.
Electromed, Inc. accounted for 57.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Electromed, Inc. | Unresolved — no canonical attribution shown | $83.81 | 57.7% | 8 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $61.38 | 42.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $145.19 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $83.81 | 8 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $61.38 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $61.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $61.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $61.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1286 | 339 |
| Prednisone | Prednisone | 734 | 244 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 622 | 109 |
| Omeprazole | Omeprazole | 449 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 91 |
| Alprazolam | Alprazolam | 355 | 55 |
| Lisinopril | Lisinopril | 308 | 79 |
| Furosemide | Furosemide | 307 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 74 |
| Ventolin Hfa | Albuterol Sulfate | 276 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 58 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 240 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 229 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 54 |
| Doxycycline Hyclate | Doxycycline Hyclate | 192 | 117 |
| Lorazepam | Lorazepam | 192 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 38 |
| Symbicort | Budesonide/Formoterol Fumarate | 169 | 47 |
| Azithromycin | Azithromycin | 164 | 102 |
| Metformin Hcl | Metformin Hcl | 164 | 39 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 162 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 41 |
| Simvastatin | Simvastatin | 156 | 43 |
| Sertraline Hcl | Sertraline Hcl | 150 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 38 |
| Losartan Potassium | Losartan Potassium | 132 | 33 |
| Eliquis | Apixaban | 130 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 114 | 24 |
| Famotidine | Famotidine | 111 | 30 |
| Valsartan | Valsartan | 110 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 29 |
| Arnuity Ellipta | Fluticasone Furoate | 108 | 23 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 108 | 34 |
| Clonazepam | Clonazepam | 105 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 99 | 23 |
| Montelukast Sodium | Montelukast Sodium | 99 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 97 | 64 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 91 | 24 |
| Trazodone Hcl | Trazodone Hcl | 90 | 17 |
| Gabapentin | Gabapentin | 89 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 18 |
| Azelastine Hcl | Azelastine Hcl | 78 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 78 | 19 |
| Ibuprofen | Ibuprofen | 77 | 26 |
| Incruse Ellipta | Umeclidinium Bromide | 71 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 69 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 68 | 37 |
| Ezetimibe | Ezetimibe | 66 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 12 |
| Xarelto | Rivaroxaban | 62 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Potassium Chloride | Potassium Chloride | 56 | 15 |
| Warfarin Sodium | Warfarin Sodium | 56 | 14 |
| Tramadol Hcl | Tramadol Hcl | 54 | 15 |
| Ondansetron Odt | Ondansetron | 51 | 12 |
| Meclizine Hcl | Meclizine Hcl | 50 | 20 |
| Levofloxacin | Levofloxacin | 49 | 27 |
| Allopurinol | Allopurinol | 48 | 12 |
| Metformin Hcl Er | Metformin Hcl | 48 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 48 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 11 |
| Diazepam | Diazepam | 42 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 42 | 13 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 40 | 12 |
| Glipizide Er | Glipizide | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Nystatin | Nystatin | 36 | 14 |
| Methylprednisolone | Methylprednisolone | 35 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 22 |
| Dulera | Mometasone/Formoterol | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Pulmicort Flexhaler | Budesonide | 25 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 13 |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Fasenra | Benralizumab | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 12 |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 14 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Trulicity | Dulaglutide | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $145.19 · 9 records | Electromed, Inc. | CHARTIS CATHETER, PULMONX CHARTIS TABLET CONSOLE, SMARTVEST, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error